Cover Image

Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, placebo‐controlled phase Ia and Ib/II studies

Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low‐density lipoprotein‐cholesterol (LDL‐C) by decreasing the expression of the LDL‐receptor on hepatic cells. Ongericimab (JS002) is a novel PCSK9 monoclonal antibody that exhibits a long‐acting LDL‐C lowering effect by...

Full description

Saved in:

Bibliographic Details
Main Authors:	Juanjuan Jiang (Author), Li Xu (Author), Lin Chai (Author), Xiaoyuan Guan (Author), Li Zhang (Author), Hong Liu (Author), Yan Yan (Author), Lili Li (Author), Yi Zhao (Author), Xuelian Bai (Author), Lei Tian (Author), Youhong Jia (Author)
Format:	Book
Published:	Wiley, 2024-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
by: article Editorial
Published: (2023)

The E670G SNP in the <it>PCSK9 </it>gene is associated with polygenic hypercholesterolemia in men but not in women
by: Beil Frank U, et al.
Published: (2006)

Increased Circulating Levels of PCSK9 and Pro-Atherogenic Lipoprotein Profile in Pregnant Women with Maternal Supraphysiological Hypercholesterolemia
by: Claudette Cantin, et al.
Published: (2022)

PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke
by: Lin Zhou, et al.
Published: (2024)

Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia
by: Karim Si-Tayeb, et al.
Published: (2016)

Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials
by: Seyyed Majid Eslami, et al.
Published: (2017)

Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
by: Karine Rodríguez-Fernández, et al.
Published: (2022)

Differential Expression of Platelet Glycoprotein Ia/IIa in Taiwan Chinese Corresponds to Glycoprotein Ia Gene Polymorphisms
by: Liu Chao-Zong, et al.
Published: (2006)

Modeling and Simulation to Support Phase Ib/IIa Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6
by: Xiange Tang, et al.
Published: (2021)

Conopeptides [V11L;V16D]ArIB and RgIA4: Powerful Tools for the Identification of Novel Nicotinic Acetylcholine Receptors in Monocytes
by: Veronika Grau, et al.
Published: (2019)

Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients
by: Chen CC, et al.
Published: (2018)

Interactions of warfarin with COVID-19 vaccine/drugs, monoclonal antibodies, and targeted anticancer agents from real-world data mining
by: Yan Gao, et al.
Published: (2024)

Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis
by: Qian Li, et al.
Published: (2022)

Sex difference in circulating PCSK9 and its clinical implications
by: Fang Jia, et al.
Published: (2022)

Hypercholesterolemia
Published: (2015)

Paediatric overview, IAS 2009
by: Polly Clayden
Published: (2009)

Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab
by: Yanyan Zhang, et al.
Published: (2024)

Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody
by: Ellen Q. Wang, et al.
Published: (2023)

Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trialResearch in context
by: Yong Huo, et al.
Published: (2023)

From IBS to DBS
by: Peter Benno MD, PhD, et al.
Published: (2016)

A Comprehensive Review of PCSK9 Inhibitors
by: Caroline Coppinger BS, et al.
Published: (2022)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
by: Martin Jozef Péč, et al.
Published: (2023)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
by: David Monteith, et al.
Published: (2017)

Irritable bowel syndrome (IBS) among Lebanese adults: unidentified IBS and associated factors
by: Gabriella Yazbeck, et al.
Published: (2023)

Clinical efficacy and safety of Chinese herbal medicine versus placebo for the treatment of chronic obstructive pulmonary disease: A systematic review and meta-analysis
by: Chan Xiong, et al.
Published: (2021)

Highlights of HIV Cure in IAS, Montréal
by: Christina K. Psomas
Published: (2022)

Neonatal Glycogen Storage Disease Ia
by: Jinping Zhang, et al.
Published: (2015)

Brain-gut interactions in IBS
by: Jakub eFichna, et al.
Published: (2012)

Clinical analysis and long-term treatment monitoring of 3 patients with glycogen storage disease type Ib
by: Caiqi Du, et al.
Published: (2021)

Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic
by: Rocio Lledo‐Garcia, et al.
Published: (2022)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
by: Kosmas CE, et al.
Published: (2020)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023)

PENGARUH PENGGUNAAN METODE GLENN DOMAN DALAM MENINGKATKAN KETERAMPILAN MEMBACA PERMULAAN PADA SISWA KELAS I SEKOLAH DASAR: Penelitian Kuasi Eksperimen Terhadap Siswa Kelas IA dan IB SDN Kubang
by: Hanny Mauludi Nurhamidah, -
Published: (2022)

Synthesized economic evidence on the cost-effectiveness of screening familial hypercholesterolemia
by: Mengying Wang, et al.
Published: (2024)

Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study
by: Zhao X, et al.
Published: (2023)

Integrated omics analysis reveals the epigenetic mechanism of visceral hypersensitivity in IBS-D
by: Yaoyao Lu, et al.
Published: (2023)

Proteome-wide mendelian randomization investigates potential associations in heart failure and its etiology: emphasis on PCSK9
by: Lichao Lin, et al.
Published: (2024)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study
by: Xue Zhao, et al.
Published: (2023)

REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics
by: Mohamed A. Kamal, et al.
Published: (2021)